Lower levels of CXCL12 and higher levels of TGFB correlate with poor HCC prognosis, but more studies are needed to validate their clinical utility in monitoring HCC treatment response [163,164]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.